APICES is pleased to share that our team has been acknowledged in the PARASEC study, a retrospective prostate cancer study presented at the ASCO GU 2025 Congress and published as a Journal of Clinical Oncology meeting abstract.
In PARASEC, investigators describe subsequent treatment patterns in Spanish prostate cancer patients who received darolutamide in the ARAMIS trial, reflecting standard clinical practice in Spain.
APICES collaborated across multiple activities, including study start-up, project management, monitoring, biostatistics, and medical writing. We would like to thank Bayer and Dr. Javier Puente for the opportunity to contribute and to be included in the acknowledgments, and we congratulate all investigators on the successful completion of this project.
You can find further information in the following link: Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study. | Journal of Clinical Oncology
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
